Copyright
©2013 Baishideng Publishing Group Co.
World J Gastroenterol. Sep 14, 2013; 19(34): 5665-5670
Published online Sep 14, 2013. doi: 10.3748/wjg.v19.i34.5665
Published online Sep 14, 2013. doi: 10.3748/wjg.v19.i34.5665
Characteristics | pH-dependent delayed release (n= 73) | Pro-drugs (n= 18) | Time-dependent sustained release (n= 11) |
Age (mean ± SE) (yr) | 47.24 ± 1.61 | 51.38 ± 2.39 | 47.54 ± 4.97 |
Gender (M/F) | 49/24 | 8/10 | 6/5 |
Extent of disease | |||
Proctosigmoiditis | 22% | 22% | 0% |
Left colitis | 10% | 11% | 0% |
Pancolitis | 68% | 67% | 100% |
Age at diagnosis (mean ± SE) | 34.88 ± 1.61 | 32.72 ± 2.30 | 31.09 ± 3.30 |
Duration of disease (yr) | 11.56 ± 0.81 | 17.22 ± 4.21 | 15.00 ± 2.62 |
Time since last 5-ASA administration (h) | 21.43 ± 1.22 | 23.88 ± 4.21 | 20.63 ± 2.52 |
- Citation: D’Incà R, Paccagnella M, Cardin R, Pathak S, Baldo V, Giron MC, Sturniolo GC. 5-ASA colonic mucosal concentrations resulting from different pharmaceutical formulations in ulcerative colitis. World J Gastroenterol 2013; 19(34): 5665-5670
- URL: https://www.wjgnet.com/1007-9327/full/v19/i34/5665.htm
- DOI: https://dx.doi.org/10.3748/wjg.v19.i34.5665